Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | PNMT | P11086 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 13/20 | 0.52 |
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PYGL | P06737 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8211623 | 0.92 | IGF1R (0.59) | IGF1RALOX15PNMTTAAR1SIGMAR1 | |
| SCHEMBL11389115 | 0.92 | IGF1R (0.59) | IGF1RALOX15PNMTTAAR1SIGMAR1 | |
| SCHEMBL7009306 | 0.92 | IGF1R (0.59) | IGF1RALOX15PNMTTAAR1SIGMAR1 | |
| SCHEMBL30019331 | 0.86 | PNMT (0.61) | IGF1RALOX15PNMTTAAR1SIGMAR1 | |
| SCHEMBL177296 | 0.86 | PNMT (0.61) | IGF1RALOX15PNMTTAAR1SIGMAR1 | |
| SCHEMBL79509 | 0.82 | DAO (0.43) | IGF1RALOX15PNMTTAAR1SIGMAR1 | |
| SCHEMBL80740 | 0.82 | SKP2 (0.42) | IGF1RALOX15PNMTTAAR1SIGMAR1 | |
| SCHEMBL81436 | 0.82 | SKP2 (0.46) | IGF1RALOX15PNMTTAAR1SIGMAR1 | |
| SCHEMBL11443994 | 0.80 | IGF1R (0.60) | IGF1RALOX15PNMTTAAR1SIGMAR1 | |
| SCHEMBL7769977 | 0.79 | IGF1R (0.39) | IGF1RALOX15PNMTTAAR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-1324990-B1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LTD (GB) | 2014-10-29 | — | — | EP | disclosed |
| CN-101730677-B | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORP | 2014-07-16 | — | — | CN | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| CN-101730677-A | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORP | 2010-06-09 | — | — | CN | disclosed |
| US-20060079525-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | ANCLIFF RACHAEL A | 2006-04-13 | — | — | US | disclosed |
| US-20050222147-A1 | Process for the preparation of morpholine derivatives and intermediates therefore | GLAXO GROUP LIMITED (GB) | 2005-10-06 | — | — | US | disclosed |
| US-20040058923-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | SMITHKLINE BEECHAM CORPORATION | 2004-03-25 | — | — | US | disclosed |
| EP-1324990-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002026722-A1 | MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2002-04-04 | — | — | WO | disclosed |
| US-5811431-A | Spiro-substituted azacyclic derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 1998-09-22 | — | — | US | disclosed |
| EP-0775140-A1 | SPIRO-SUBSTITUTED AZACYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LTD. (GB) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996005203-A1 | SPIRO-SUBSTITUTED AZACYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 1996-02-22 | — | — | WO | disclosed |
| US-5262420-A | Phenylalkylpyridines | IDEMITSU KOSAN CO., LTD. (JP) | 1993-11-16 | — | — | US | disclosed |
| EP-0383950-A1 | PYRIDINE DERIVATIVES AND INSECTICIDAL AND MITICIDAL AGENT CONTAINING SAME AS ACTIVE INGREDIENT | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058923-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | CCR1, MALT1, REL | IGF1R 1578/4885ALOX15 410/4885PNMT 2321/4885 |
| US-20050222147-A1 | Process for the preparation of morpholine derivatives and intermediates therefore | NISCH, MYO3B, CYP11B2 | IGF1R 4437/4885ALOX15 3898/4885PNMT 681/4885 |
| US-20060079525-A1 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases | ARG1, ARG2, NFKBIA | IGF1R 3165/4885ALOX15 1022/4885PNMT 3847/4885 |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HLA-B, HLA-A, HLA-C | IGF1R 4690/4885ALOX15 1268/4885PNMT 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.